Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment
of oedema associated to heart failure, kidney or liver disease and either in the treatment of
arterial hypertension (alone or combined with other anti-hypertensive drugs). It has been
developed a new formulation of Torasemide (Torasemide prolonged release).
The aim of this trial is to study the effects of Torasemide prolonged released in comparison
with furosemide, in the reduction of myocardial fibrosis in patients with chronic heart
failure (Class II-IV of the New York Heart Association Classification.